# Editas Medicine Inc. (EDIT)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $220M  
**Price:** $2.48 (-6.42%)

> Editas Medicine Inc. is a clinical-stage biotechnology company focused on developing CRISPR-based gene editing therapies for serious diseases. The company harnesses CRISPR technology, which enables precise revision, removal, and replacement of DNA sequences, to create transformative genomic medicines targeting conditions such as rare genetic disorders, sickle cell disease, and beta-thalassemia. Its pipeline features experimental programs like EDIT-101 for Leber congenital amaurosis, an inherited form of blindness, and others utilizing Cas9 and Cas12a nucleases for durable treatments. Editas Medicine Inc. advances these therapies through discovery, development, manufacturing, and potential commercialization, aiming to address unmet needs in the healthcare sector. Operating in the biotechnology industry, it contributes to the growing field of gene therapy by leveraging proprietary platforms to treat a broad range of debilitating illnesses. Founded in 2013 and headquartered in Cambridge, Massachusetts, with facilities in Boulder, Colorado, Editas Medicine Inc. remains dedicated to delivering innovative solutions for patients worldwide.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $41M | — | -$160M | -$160M | $-1.80 |
| 2024 | $32M | — | -$251M | -$237M | $-2.88 |
| 2023 | $78M | — | -$169M | -$153M | $-2.02 |
| 2022 | $20M | — | -$226M | -$220M | $-3.21 |
| 2021 | $26M | — | -$193M | -$193M | $-2.85 |
| 2020 | $91M | — | -$135M | -$116M | $-1.98 |
| 2019 | $21M | — | -$141M | -$134M | $-2.68 |
| 2018 | $32M | — | -$114M | -$110M | — |
| 2017 | $14M | — | -$120M | -$120M | — |
| 2016 | $6M | — | -$97M | -$97M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $187M | $159M | $27M | $147M | $54M |
| 2024 | $342M | $207M | $134M | $132M | $57M |
| 2023 | $499M | $150M | $349M | $124M | — |
| 2022 | $514M | $154M | $361M | $142M | — |
| 2021 | $677M | $124M | $554M | $204M | — |
| 2020 | $573M | $179M | $394M | $140M | — |
| 2019 | $509M | $246M | $262M | $238M | — |
| 2018 | $420M | $184M | $236M | $135M | — |
| 2017 | $373M | $165M | $208M | $147M | — |
| 2016 | $229M | $95M | $135M | $185M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$165M | $607,000 | -$166M |
| 2024 | -$210M | $9M | -$219M |
| 2023 | -$132M | $5M | -$137M |
| 2022 | -$177M | $4M | -$181M |
| 2021 | -$164M | $8M | -$172M |
| 2020 | -$180M | $7M | -$187M |
| 2019 | -$41M | $6M | -$47M |
| 2018 | -$46M | $5M | -$50M |
| 2017 | -$9M | $2M | -$11M |
| 2016 | -$50M | $3M | -$54M |
| 2015 | -$5M | $1M | -$7M |

Source: [CompaniesByCap](https://companiesbycap.com/company/EDIT)